CHEMOTACTIC ACTIVITY GENERATED FROM THE FIFTH COMPONENT OF COMPLEMENT BY PLASMA KALLIKREIN OF THE RABBIT*

BY ROGER C. WIGGINS, PATRICIA C. GICLAS, AND PETER M. HENSON

From the Department of Immunopathology, Research Institute of Scripps Clinic, La Jolla, California 92037; and the Department of Pediatrics, National Jewish Hospital, and Departments of Medicine and Pathology, University of Colorado Medical School, Denver, Colorado 80206

The proteins of the complement and coagulation systems are major transducing mechanisms of plasma whereby small initiating signals are amplified and translated into biological events. To date, these systems have largely been studied in isolation, although interactions between them may be expected. Indeed the similarity of structure and mechanism of inhibition of Cls and Clr of the complement system (1) and Hageman factor, Factor XI, and prekallikrein of the intrinsic coagulation system (2) are so similar as to raise the possibility of genetic reduplication in their development. Furthermore, plasma kallikrein has been shown to be capable of cleaving and activating both Cls and Clr (3).

In the present study, we report the ability of kallikrein purified from rabbit plasma to generate chemotactic activity for rabbit neutrophils from rabbit C5. The study was prompted by previous reports that human kallikrein was directly chemotactic for human neutrophils (4), an observation that we have not been able to confirm for the rabbit system. The results suggest the existence of a novel interaction between the Hageman factor and complement systems which may have biological relevance.

Materials and Methods

Purified Proteins from Rabbit Plasma

**HAGEMAN FACTOR (HF).** 1 HF and the two-chain, 80,000-Mr form of activated HF (α-HFa) were purified from rabbit plasma (Fig. 1). 2

**PREKALLIKREIN (PK).** PK was purified from citrated rabbit plasma in collaboration with Dr. William McGuire of the Research Institute of Scripps Clinic, La Jolla, Calif., by a three-step procedure.

**Step 1. Solid-Phase Immunoabsorption of PK from Rabbit Plasma.** An IgG fraction of monospecific...
Fig. 1. Proteins purified from rabbit plasma (used in these studies) analyzed by SDS-PAGE in the presence (R) and absence (NR) of β-mercaptoethanol. Zymogen HF is a single polypeptide chain of 82,000 M₉. HFa (enzyme) is dissociated into fragments of 52,000 and 28,000 M₉ in the presence of reducing agents. Residual native HF remains at 82,000 M₉ in the presence of reducing agents. PK zymogen is a single polypeptide chain of 85,000 M₉. Upon activation to kallikrein, the single polypeptide chain is cleaved into fragments of 55,000 and 35,000 M₉. High-Mr kininogen is a single polypeptide chain of 100,000 M₉ in the presence and absence of reducing agents. Rabbit C5 is a two-chain disulfide-linked molecule of unreduced 180,000 M₉, which dissociates into chains of 130,000 and 50,000 M₉ in the presence of reducing agent. HF, PK and high-Mr kininogen are shown here on 7.5% SDS gels, whereas C5 is shown as a 5% SDS gel.

goat-anti-rabbit PK was prepared by: (a) absorption of plasma with kaolin (25 mg kaolin/ml) incubated for 10 min at 37°C and then centrifuged for 15 min at 5,000 g to remove the kaolin; (b) dialysis of the kaolin-absorbed serum against 0.01 M phosphate buffer, pH 7.7, followed by absorption in batches using DEAE-cellulose (10 g/g protein) equilibrated in the above buffer; (c) concentration of the globulin fraction by precipitation with 50% ammonium sulfate and subsequent dialysis against 0.1 M phosphate buffer, pH 7.5. The IgG fraction thus produced contained no detectable goat kallikrein (<20 ng/ml), as measured by the chromogenic tripeptide assay.

This IgG fraction in 0.1 M phosphate buffer, pH 7.5, was coupled to cyanogen bromide-activated Sepharose-4B (5) at a ratio of 5 mg of protein/1 g of Sepharose-4B. The washed beads were incubated overnight at +4°C with 5 mM diisopropyl fluorophosphate in water. The beads were rewashed and poured into a 2.5- X 30-cm plastic column to a bed height of 26 cm. The column was washed with 5 M guanidine, followed by 0.1 M Tris buffer, pH 7.4, containing 1 M NaCl, 20 mM EDTA, 10 mM benzamidine, 0.05% hexadimethrene bromide (Polybrene; Aldrich Chemical Co., Inc., Milwaukee, Wis.) and 0.02% sodium azide.

Citrated normal rabbit plasma (200 ml) was made 10 mM with benzamidine, 0.7 M with NaCl, 20 mM EDTA, 0.05% Polybrene, and 0.02% sodium azide. The plasma was run through the column at room temperature at a flow rate of 100 ml/h. The column was washed with 10-column volumes of starting buffer and then eluted with 5 M guanidine (Sigma Chemical Co., St. Louis, Mo.). The fractions calculated to contain the initial guanidine step and one-column volume thereafter were pooled for the second step.

Step 2. Ion-Exchange Chromatography on SP-Sephadex C-50. The pool from Step 1 (200 ml) was dialyzed against 0.1 M acetate buffer, pH 5.3, containing 0.04 M NaCl, 2 mM EDTA, 1 mM benzamidine, 0.05% Polybrene, and 0.02% sodium azide. 2 g of SP-Sephadex C50 (Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, N. J.) hydrated overnight in the above buffer was poured into a siliconized 2.5- X 30-cm column. After two changes of dialysis, the column was washed with four-column volumes of starting buffer. A step elution was effected with 0.1 M acetate buffer, pH 5.3, containing 0.35 M NaCl (= 40 mS).

Step 3. Affinity Chromatography on Concanavalin A-Sepharose. The pooled fractions containing PK (40 ml) were dialyzed against 0.1 M sodium phosphate buffer, pH 7.5, containing 1 M NaCl, 0.02% sodium azide, and 1 mM benzamidine. The dialyzed material was loaded at 3
ml/h onto a 1.7-cm diameter siliconized glass column containing 6 ml of concanavalin-A Sepharose. The column was washed with 60 ml of the above buffer. Elution of PK was effected with the above buffer containing 0.5 M α-D-methyl glucoside at 2 ml/h. Analysis of the eluted protein from the above column by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under both reducing and nonreducing conditions showed a single protein band with a molecular weight (Mr) of 83,000 (Fig. 1). Assays of PK were performed by immunodiffusion, using goat anti-rabbit PK antiserum.

**Kallikrein Generation.** Kallikrein was generated by incubating PK with α-HFa in the following manner. PK (1 ml, 220 μg) was incubated with α-HFa (50 μl, 10 μg) in the presence of 10 μl 2 M Tris buffer, pH 8.0, for 60 min at 37°C. The HFa was not removed from the kallikrein preparation, but constituted <1% of the protein present. The extent of proteolytic cleavage of prekallikrein as measured by SDS-PAGE (Fig. 1) varied between 58 and 94% in different preparations. The enzymatic activity of kallikrein in each preparation was measured colorimetrically using the tripeptide substrate N-Benzoyl-L-Pro-L-Arg-p-nitroanalide (Bz-pro-phe-arg-pNA; Vega Biochemicals, Tucson, Ariz.) under the conditions described below. The calculated Kcat value obtained for different preparations varied between 300 and 400 min⁻¹. The PK purified in this manner showed a line of identity with rabbit PK purified by ion-exchange chromatography (6) and generously donated by Dr. Richard Ulevitch of the Research Institute of Scripps Clinic.

**High-Mr Kininogen.** High-Mr kininogen was purified from rabbit plasma by a three-step procedure.

**Step 1. Solid-Phase Immunoabsorption of High-Mr Kininogen from Rabbit Plasma.** Goat anti-rabbit high-Mr kininogen was coupled to Sepharose 4B as described for PK. Citrated normal rabbit plasma was passed over an anti-high-Mr, kininogen-Sepharose 4B column and eluted with 5 M guanidine as described above.

**Step 2. DEAE-Sephadex A50 Ion-Exchange Chromatography.** The pool from Step 1 (500 ml) was dialyzed against buffer containing 0.4 M Tris, 0.1 M succinic acid, pH 8.2, containing 40 mM NaCl, 10 mM benzamidine, 2 mM EDTA, and 0.02% sodium azide. This material was loaded onto a 2.5- × 3 cm siliconized column containing 3 g of DEAE-Sephadex A50 equilibrated in the starting buffer. The column was washed with five-column volumes of starting buffer and eluted with a gradient consisting of 150 ml of the starting buffer in the proximal chamber and 150 ml of 0.3 M Tris, 0.12 M succinic acid, pH 7.4, containing 0.3 M NaCl, 2 mM EDTA, 10 mM benzamidine, and 0.02% sodium azide. The high-Mr, kininogen eluted in the distal shoulder of the protein peak, whereas low-Mr, kininogen eluted in the proximal shoulder of the peak.

**Step 3. SP-Sephadex Ion-Exchange Chromatography.** The pool containing high-Mr, kininogen from Step 2 (70 ml) was dialyzed against 0.1 M acetate buffer, pH 5.3, containing 75 mM NaCl, 10 mM benzamidine, 2 mM EDTA, and 0.02% sodium azide. This material was loaded onto 2 g SP-Sephadex C50 equilibrated in the above buffer. The column was washed with 10-column volumes of the above buffer and eluted with a salt gradient to 0.4 M NaCl in 0.1 M acetate buffer, pH 5.3. The eluted material analyzed by SDS-PAGE in the presence and absence of reducing agents revealed a single predominant protein band with an Mr of 100,000 (Fig. 1). This material had a specific clotting activity of 6.5 clotting U/mg, where 1 U is the amount of rabbit high-Mr, kininogen present in 1 ml of plasma when assayed in human high-Mr, kininogen-deficient (Fitzgerald) plasma.

**C5.** C5 was purified from normal rabbit plasma by euglobulin precipitation (pH 5.0), and ion-exchange and gel-filtration chromatography as previously described (7). Rabbit C5 thus prepared was homogeneous on SDS-PAGE (Fig. 1) and contained no detectable C3 by functional or immunochemical analysis.

**EAC423 Preparation.** Sheep erythrocytes bearing the classical pathway C5 convertase were prepared from human complement components by the method of Rapp and Borsos (8).

**Chromogenic Tripeptide Assay.** The synthetic chromogenic tripeptide Bz-pro-phe-arg-pNA HCl was dissolved in 0.1 M Tris, pH 8.3, containing 0.05 NaCl and 0.02% sodium azide at a final concentration of 0.1 mg/ml. The sample to be assayed (2-5 μl) was added to a 300-μl volume of substrate in a cuvette and the change in absorbance was measured at 405 nM. The
values for $K_{cat}$ were calculated using a molar extinction coefficient of 10,000 M$^{-1}$ cm$^{-1}$ at 405 nM.

**Neutrophil Function Assays.** These were performed using leukocytes isolated from New Zealand White rabbits as previously described (9). The modified Boyden assay was performed using the two-filter technique of Keller et al. (10). The leading front method was performed according to Zigmond and Hirsch (11). Each sample was measured in triplicate and the results were expressed as the mean ± 1 SD from the mean. For each assay positive (5% zymosan-activated rabbit serum [ZARS] and negative (Hanks' balanced salt solution-bovine serum albumin [HBSS-BSA]) controls were incorporated. The Keller assay and leading front assays were sensitive to 5 ng and 0.2 ng of human C5a, respectively (9).

**Kinin Bioassay.** This was performed using the estrogen-sensitized rat uterus assay as previously described (12).

**SDS-PAGE.** Analysis by SDS-PAGE was performed using cylindrical gels and the Weber-Osborne system (13). Gels were stained for protein with Coomassie Blue dye or cut into 1.2-mm slices and counted for $^{125}$I on an automated γ-counter (Searle Radiographics, Inc., Des Plaines, Ill.).

**Miscellaneous.** Protein determinations were performed by the method of Lowry et al. (14) using BSA (5 times recrystallized; Reheis Chemical Co., Chicago, Ill.) as a standard. Radiolabeling was performed with $^{125}$I using the chloramine T method (15). Neutrophil enzyme release was measured as described in reference 16.

### Results

**Chemotactic Activity Generated from C5 by Plasma Kallikrein.** When rabbit C5 was incubated with rabbit plasma kallikrein, chemotactic activity could easily be demonstrated (Table I). In contrast, no chemotactic activity could be demonstrated when the zymogen PK was tested with C5 under identical conditions. Chemotactic activity was also generated when rabbit C5 was incubated with α-HFa, trypsin, (Table I), or EAC423. No chemotactic activity was produced when C5 was absent from the incubation mixtures, or when intact C5 alone was assayed.

**Direct Chemotactic Effect of Plasma Kallikrein.** Because plasma kallikrein has been reported to be directly chemotactic for neutrophils (4), we investigated the ability of rabbit plasma kallikrein alone to attract rabbit neutrophils. As shown in Table II, over a dose-range from $2.5 \times 10^{-7} - 10^{-10}$ M kallikrein, no detectable chemotactic activity was demonstrated.

| Reagent  | Chemotactic activity (cells/HPF* ± 1 SD) |
|----------|----------------------------------------|
|          | No C5                                 | Added C5
| Buffer   | 2.4 ± 2.2                              | 2.0 ± 0.9  |
| Kallikrein | 0.6 ± 0.4                          | 50.1 ± 3.8 |
| PK       | 0.2 ± 0.3                              | 1.8 ± 0.4  |
| α-HFa    | 1.5 ± 2.3                              | 25.8 ± 7.7 |
| Trypsin  | 1.5 ± 1.2                              | 20.4 ± 1.5 |
| EAC423   | 3.0 ± 0.9                              | 18.2 ± 2.4 |
| ZARS     | 87.8 ± 23.6                            | —          |

Chemotactic activity was generated when kallikrein (1.4 μg), α-HFa (2.4 μg), trypsin (0.2 μg), and EAC423 cells ($1 \times 10^5$) were incubated with C5 (10 μg). All incubations were for 20 min at 37°C with the exception of trypsin, which was for 2 min at 22°C. The reaction was stopped with SBTI (40 μg) added for 5 min at 22°C. ZARS (5%) was used as a positive control. Each assay was performed in triplicate.

* High power field.
TABLE II

| Plasma kallikrein | Boyden chamber (cells/HPF* ± 1 SD) | Leading front (distance ± 1 SD) |
|-------------------|-----------------------------------|--------------------------------|
| $2.5 \times 10^{-7}$ | 1.6 ± 1.2                         | 14.3 ± 0.6                     |
| $10^{-7}$         | 3.2 ± 2.0                         |                                |
| $2.5 \times 10^{-8}$ | 0.7 ± 0.1                         | 23.0 ± 4.6                     |
| $10^{-8}$         | 0.6 ± 0.2                         |                                |
| $2.5 \times 10^{-9}$ | 1.5 ± 1.6                         | 26.7 ± 3.8                     |
| $10^{-9}$         | 0.6 ± 0.6                         |                                |
| $2.5 \times 10^{-10}$ |                                | 27.7 ± 4.9                     |
| Buffer control    | 0.8 ± 0.4                         | 29.3 ± 5.1                     |
| 5% ZARS           | 87.8 ± 4.0                        | 145.0 ± 20                     |

Plasma kallikrein at the above concentrations was tested for chemotactic activity in the presence of HBSS containing BSA (20 mg/ml) by both the modified Boyden assay and the leading front method ($n = 3$).

* High power field.

activity was observed using the modified Boyden chamber (see Materials and Methods). This was found consistently in four experiments using two different kallikrein preparations. Furthermore, using the more sensitive leading front method (see Materials and Methods), again, no chemotactic activity could be detected (Table II) in two experiments.

**Enzymatic Activity of the Rabbit Plasma Kallikrein**

To confirm that the kallikrein used in these experiments was biologically active, the following assays were performed.

**Tripeptide Hydrolysis.** The rate of hydrolysis of the synthetic substrate Bz-pro-phe-arg-pNA was measured spectrophotometrically. The calculated $K_{cat}$ value ranged from 300 to 460 min$^{-1}$ under the conditions of assay (see Materials and Methods).

**Proteolytic Cleavage of Radiolabeled Substrates.** The ability of the kallikrein to cleave its natural substrates, HF and high-M$_r$ kininogen, was measured. $^{125}$I-HF (200 µg, 0.2 µCi) or $^{125}$I high-M$_r$ kininogen (250 µg, 0.2 µCi) were incubated with dilutions of kallikrein and PK in the presence of 0.1 M Tris, pH 7.4, and BSA (1 mg/ml). Typical cleavage patterns are shown in Fig. 2, where $^{125}$I-HF was cleaved into fragments of 28,000 and 50,000 M$_r$, and $^{125}$I high-M$_r$ kininogen was cleaved to one major fragment containing $^{125}$I with an M$_r$ of 70,000.

**Kinin Generation.** The ability of kallikrein to release biologically active kinin from rabbit high-M$_r$-kininogen was measured using an estrogen-sensitized rat uterus bioassay system (Table III).

As confirmed by these studies, the kallikrein was capable of releasing biologically active kinin from high-M$_r$ kininogen in association with proteolytic cleavage of the molecule. In contrast, PK did not cleave high-M$_r$ kininogen and did not generate kinin. However, if $\alpha$-HFa was incubated with PK, the PK was activated with subsequent release of kinin from high-M$_r$ kininogen. We conclude that all the proteins used in these studies were capable of biological activity and that the kallikrein preparation was indeed kallikrein.

**Chemotactic Effect of HF and High-M$_r$ Kininogen.** Because kallikrein appeared not to
Fig. 2. Radioactivity profiles from reduced SDS-PAGE of $^{125}$I-HF and $^{125}$I-high-Mr kininogen incubated with PK or with kallikrein. Kallikrein caused proteolytic cleavage of high-Mr kininogen into a major $^{125}$I-containing fragment of 70,000 M_r. Kallikrein caused cleavage of $^{125}$I-HF into fragments of 52,000 and 28,000 M_r.

**TABLE III**

| Kallikrein | PK | α-HFa | High-Mr kininogen | Response time | Bradykinin equivalents |
|------------|----|-------|-------------------|---------------|-----------------------|
| 0.9 µg     | 0.9 µg | 1.8 µg | 7 µg              | 3.0           | 38.0                  |
| +          | -    | -     | +                 | NR            | <4                    |
| -          | +    | -     | +                 | NR            | <4                    |
| -          | -    | +     | +                 | 3.5           | 30.4                  |
| +          | -    | -     | +                 | NR            | <4                    |
| -          | +    | +     | -                 | NR            | <4                    |

Purified proteins of the rabbit HF system were incubated together for 10 min at 37°C in the presence of 0.05 M Tris buffer containing BSA (1 mg/ml) in a total volume of 80 µl. 100 µl of hot (100°C) saline was added to each tube and the samples were boiled for 4 min before the assay using an isolated estrogen-sensitized rat uterus (see Materials and Methods). NR, no response.

have any chemotactic activity, the natural kallikrein substrates in their activated form (α-HFa and kinin-free high-M_r kininogen) were tested for their ability to attract cells. α-HFa, the two-chain, 80,000-M_r form of activated HF, was tested over a dose
range of $7 \times 10^{-7}$–$7 \times 10^{-10}$ M using the Boyden assay system. No chemotactic activity was observed (data not shown).

Rabbit high-Mr kininogen (220 μg) was preincubated with rabbit kallikrein (20 μg) for 30 min at 37°C in the presence of 0.1 M Tris, pH 7.4. No chemotactic activity could be detected in this incubation mixture over a dose range of $2.5 \times 10^{-7}$–$2.5 \times 10^{-10}$ M high-Mr kininogen (data not shown).

We conclude that neither kallikrein nor HFα nor high-Mr kininogen is capable of attracting rabbit neutrophils under the conditions of study.

Finally, PK (40 μg/ml), HF (22 μg/ml), α-HFα (3 μg/ml), and high-Mr kininogen (55 μg/ml) were incubated together for 20 min at 37°C in the presence of BSA (1 mg/ml). Activation of protein was confirmed by measurement of kinin generation by bioassay. No chemotactic activity could be demonstrated using the Boyden method. We conclude that no detectable chemotactic fragments were generated during activation of these proteins.

**Dose-Response Curve of Generation of Chemotactic Activity from C5 by Kallikrein.** A dose-response curve of rabbit plasma kallikrein incubated with rabbit C5 (at a final concentration of 100 μg/ml) demonstrated the production of chemotactic activity by kallikrein down to a level of ~1 μg/ml (Fig. 3) (the physiological concentration of PK in rabbit plasmas is ~25 μg/ml). Thus, plasma kallikrein at physiological concentration appears to be capable of generating chemotactic activity from C5.

As indicated in Table I, α-HFα also generated chemotactic activity from C5. A dose-response curve for α-HFα indicated that α-HFα was about one-third as active as kallikrein in this respect.

**Kallikrein-blocking Studies.** To establish whether the kallikrein effect on C5 could be due to a contaminating enzyme, blocking studies were performed with anti-kallikrein IgG and with soybean trypsin inhibitor (SBTI). Rabbit kallikrein (20 μg/ml) was incubated with anti-PK or anti-HF antisera at a final concentration of 8 mg/ml for 20 min at 22°C in the presence of 0.1 M Tris buffer, pH 7.4. The kallikrein preparations were then assessed for their ability to (a) hydrolyse Bz-pro-phe-arg-pNA; (b) generate kinin from purified high-Mr kininogen as measured by the rat uterus bioassay; and (c) generate chemotactic activity from C5. For each assay system, the amount of the kallikrein-anti-HF preparation (control) used was on the upper portion of the dose-response curve. The response of the kallikrein-anti-PK preparation was

![Fig. 3. Dose-response curve for kallikrein-induced chemotaxis in the presence of C5 (10 μg). The final incubation volume was 100 μl in the presence of 0.05 M Tris, pH 7.6, containing 0.5 mg/ml ovalbumin. After incubation for 20 min at 37°C, SBTI (40 μg) was added for 5 min at 22°C before chemotaxis assay.](image)
compared with this value and expressed as the percent of the control. As shown in Fig. 4, the anti-PK IgG blocked the tripeptide hydrolysis response by only 26%, whereas the chemotaxis and kinin generation responses were blocked by 41 and 68%, respectively. This difference in blocking effect by antibody was reproducible and was not effected by changing the ratio of kallikrein to anti-PK. It probably reflects greater steric hindrance by the anti-PK IgG-kallikrein complex for the larger substrates and possibly the requirement for two clips to liberate kinin from kininogen.

Kallikrein (5 µg) was also incubated with various doses of STBI (2.9, 1.5, and 0.7 µg) to generate inactive SBTI-kallikrein complexes in varying proportions such that ~¼, ½, and ¾ of the kallikrein molecules would remain active. These partially inhibited kallikrein preparations were compared with a noninhibited control for their ability to (a) hydrolyse the tripeptide Bz-pro-phe-arg-pNA; (b) generate bradykinin from purified high-Mr kininogen; and (c) generate a chemotactic response from C5. As shown in Fig. 5, the ability of SBTI to inhibit kallikrein activity on three different substrates was similar, indicating that the kallikrein-induced chemotactic response was due to kallikrein itself and not due to a contaminating enzyme.

**Nature of the Chemotactic Substance Generated from C5 by Kallikrein**

**SECRETION OF β-GLUCURONIDASE FROM NEUTROPHILS.** C5a is capable of causing specific release of granular contents from cytochalasin B-treated neutrophils (9). To determine whether kallikrein-treated C5 generated a fragment capable of causing specific release as well as chemotaxis, the following experiment was performed.

Isolated rabbit neutrophils were suspended in HBSS in the presence of BSA (0.25%).
Aliquots containing $4 \times 10^6$ neutrophils were incubated for 5 min at 37°C with cytochalasin B (5 μg/ml prepared at 5 mg/ml in dimethyl sulfoxide). The cells were then exposed to C5 (25 μg), which had been preincubated for 120 min at 37°C either with buffer, kallikrein (550 ng), EAC423 (5 × 10⁷ cells), or trypsin (300 ng), after which SBTI (1 μg) was added to each incubation mixture and allowed to stand for 5 min at 22°C. Purified human C5a (15 ng) (generously donated by Robert O. Webster, National Jewish Hospital and Research Center, Denver, Colo.) was used as a positive control. The release of a granular enzyme, β-glucuronidase, and a cytosol enzyme, lactic dehydrogenase (LDH), was measured as previously described (16, 17) after 30 min incubation with the stimulus. No significant release of LDH occurred (<5% of total releasable by detergent), indicating that no cell lysis had occurred. The base-line release of β-glucuronidase with C5 alone after 120 min at 37°C was 9.8% of the total enzyme releasable by detergent from an equivalent number of cells. In contrast, incubation of C5 with kallikrein, EAC423 cells or trypsin resulted in 45.3, 51.4, and 49.4% β-glucuronidase release, respectively. Purified human C5a caused 53.4% release. Thus kallikrein, like EAC423 cells and trypsin, generated from C5 a factor that caused rabbit neutrophils to release a specific granular enzyme.

Effect of carboxypeptidase N. Carboxypeptidase N cleaves the C-terminal arginine from human C5a to generate C5a des arg, a molecular species with 100-fold less secretagogue activity than C5a (9). To determine whether the chemotactic factor generated from C5 by plasma kallikrein was susceptible to carboxypeptidase N, the following experiment was performed. Kallikrein or trypsin was incubated with C5 under the conditions described above. Human C5a and the rabbit C5-kallikrein and C5-trypsin incubates were treated for 5 min at 22°C with 1 mg SBTI to inhibit the enzymes and then incubated with or without carboxypeptidase N (endopeptidase-free; Worthington Biochemical Corp., Freehold, N. J.), 1% carboxypeptidase N (wt/wt) in 1% NaHCO₃, pH 7.0, for 15 min at 37°C. The ability of human C5a and the C5-kallikrein and C5-trypsin incubates to release β-glucuronidase in the absence of carboxypeptidase N were 64, 61, and 60% of the total detergent-releasable enzyme, respectively. After incubation with carboxypeptidase N, the respective values were 18, 25, and 16%. Thus, carboxypeptidase N partially inhibited the specific release of β-glucuronidase from neutrophils by the kallikrein C5 incubate. Furthermore, the extent of inhibition was similar to that seen for carboxypeptidase-treated human C5a.

Cleavage fragments of C5 generated by kallikrein. Studies were performed to determine the size of cleavage fragments generated from C5 by incubation with kallikrein. Fragments of C5 were visualized by both Coomassie Blue staining and autoradiography of ¹²⁵I-C5 before and after incubation with kallikrein. Analysis of the cleaved proteins in the presence and absence of reducing agents was performed on exponential gradient (8–20%) acrylamide gels in the presence of SDS. In the absence of reducing agents, a single cleavage fragment was consistently seen by autoradiography with an apparent molecular weight of ~14,000. In the presence of reducing agents, only the α-chain of rabbit C5 appeared to be cleaved when analysed both by autoradiography and stained gels. In the presence of reducing agents, fragments were observed with apparent molecular weights of 50,000, 34,000, and 25,000 in addition to the 14,000-M₉ fragment. These findings indicate that plasma kallikrein can release a 14,000-M₉ fragment.
from C5 and that the C5 molecule may also be cleaved by kallikrein at additional sites. The 14,000-Mr fragment could be a chemotactic C5a-like molecule.

**Generation of Chemotactic Activity in Kaolin-activated Plasma.** Addition of kaolin to plasma results in activation of the HF system with consequent kallikrein activation. Previous studies have reported both that chemotactic activity is (4) or is not (18) generated during kaolin activation of plasma. To resolve this discrepancy, rabbit plasma (containing 0.38% sodium citrate) was activated with kaolin (10 mg/ml final concentration, 10-min incubation at 37°C) under conditions that activate >70% of PK to kallikrein. As a negative control, citrated plasma was used, and as a positive control, citrated plasma was activated with zymosan. Each plasma was assayed for chemotactic activity in triplicate. The results are shown in Table IV. Although there was a consistent trend for kaolin-activated plasma to contain more chemotactic activity than control plasma, this was only statistically significant when low concentrations of plasma were used. These results and other studies consistently indicated that kaolin-activated plasma tends to contain more chemotactic activity than control plasma but much less chemotactic activity than zymosan-activated plasma. However, when kaolin was added to zymosan-activated rabbit plasma at a final concentration of 50 mg/ml, the chemotactic activity was reduced from 38.7 ± 10.3 to 3.5 ± 1.6 (n = 3, P < 0.01). Thus, at high concentrations kaolin blocks detectable chemotactic activity, probably by binding positively charged C5a to the negatively charged kaolin surface.

Therefore, although the assessment of chemotactic activity in kaolin-activated plasma is complicated by the probable binding of C5a to kaolin, the chemotactic activity of plasma did appear to increase after incubation with kaolin.

**Discussion**

Previous studies using partially purified preparations of human plasma kallikrein have indicated that kallikrein itself might be directly chemotactic for neutrophils (4, 19–21). This observation is surprising, because no other enzyme is known to have direct chemotactic activity. In particular, trypsin, with its ability to hydrolyse peptide

| Plasma concentration used | Control plasma, (mean ± 1 SD) | Kaolin-activated plasma, (mean ± 1 SD) | Zymosan-activated plasma, (mean ± 1 SD) |
|---------------------------|-------------------------------|----------------------------------------|----------------------------------------|
| %                         |                               |                                        |                                        |
| 0.5                       | 3.2 1.8                       | 5.5 0.1‡                               | 71.3 38.2‡                             |
| 1.0                       | 3.1 1.5                       | 4.9 0.8                                | 77.4 20.9§                            |
| 5.0                       | 4.5 2.4                       | 8.4 2.2                                | 107.6 25.9§                           |
| 10.0                      | 5.0 1.6                       | 5.6 1.7                                | 103.1 21.6§                           |

Chemotactic activity present in plasmas after incubation alone or with kaolin (5 mg/ml) or zymosan (5 mg/ml) for 10 min at 37°C. Each sample was tested in triplicate as described in Materials and Methods. Section marks indicate indicate the degree of significance between the treated and control plasmas as indicated by a paired t-test.

* High power field.
‡ P < 0.05.
§ P < 0.01.
bonds adjacent to positively charged residues in a rather unrestricted fashion, is not itself chemotactic. This contrasts with the fact that the trypsinlike arginine esterase plasma kallikrein appeared to require enzymatic activity for its chemotactic activity (4).

The findings from this study, using highly purified and well-characterized proteins and cells of rabbit origin, indicate that rabbit plasma kallikrein is not chemotactic. In addition, HF, HFa, high-Mr kininogen, activated high-Mr, kininogen, and PK were not chemotactic alone or when incubated together so that activation occurred in the incubation mixture. Thus, activation of the purified proteins of the HF system did not generate a chemotactic fragment that was detectable under the conditions employed in this study.

However, plasma kallikrein was capable of producing a chemotactic effect if C5 was included in the incubation mixture. Plasma kallikrein at concentrations as low as 1 µg/ml appeared to be capable of generating a chemotactic effect from C5 when the latter was present at physiological concentrations (100 µg/ml). It is unlikely that this effect was due to a contaminating protease that was not detected in the kallikrein preparation by SDS or alkaline gel analysis, because specific anti-kallikrein IgG inhibited kallikrein-mediated kinin generation and kallikrein-mediated chemotaxis to a similar extent. The finding that the antibody only partially inhibited both effects provides stronger evidence that the same enzyme was involved. Furthermore, SBTI also inhibited the kinin-generating, chemotactic, and tripeptide-hydrolysing effects to the same extent. We conclude that the chemotaxis generation was due to the action of plasma kallikrein on C5.

The nature of the chemotactic substance generated from C5 by kallikrein appeared to be similar to C5a. Thus, it was chemotactic, it stimulated β-glucuronidase release from cytochalasin B-treated neutrophils, it was sensitive to carboxypeptidase N digestion, and its activity was associated with the generation of a low-Mr fragment (~14,000) from C5. In addition, the amount of chemotactic and secretagogue activity generated from C5 by kallikrein was consistent with calculations of the amount of C5a activity that could be released from the quantity of C5 in the initial incubation mixture. Furthermore, kallikrein, like trypsin, is an arginine esterase and the C-terminal amino acid of both human and porcine C5a is arginine (22). From the above considerations, it seems likely that C5a can be released from rabbit C5 by plasma kallikrein.

The potential importance of kallikrein in liberating C5a from C5 in vivo is not yet known. However, during tissue injury, substances such as bacterial lipopolysaccharides (23), collagen and elastin (24-26), basement membrane (27), and sodium urate and pyrophosphate crystals (28) may act as negatively charged surfaces upon which assembly and activation of the molecules of the HF system can occur (29). Damaged endothelial cells contain an enzyme capable of directly activating HF (12). Under these conditions, kallikrein could be generated that might then release C5a from C5. The importance of the capacity of C5a to bind to negatively charged substances, thereby creating a stable surface-bound gradient for orientation of migrating neutrophils, has previously been emphasized (30). Thus, it is not surprising that negatively charged agents, such as kaolin, used to activate the HF system in the laboratory, should also have the capacity to bind C5a. Although this fact makes the measurement of C5a in the presence of a kallikrein-generating system in plasma more difficult, it
may reflect the importance of exposure of negatively charged substances such as basement membrane, collagen, or elastin during tissue injury. It is possible that these negatively charged substances may not only allow activation of the HF system with kallikrein generation, but may also bind C5a locally generated by kallikrein with consequent effects on vascular permeability and attraction of two major effector cells of inflammation: neutrophils and macrophages (31-34).

There remains the apparent discrepancy between the findings described in this study using rabbit proteins and previous observations using human proteins (4, 19–21). One possible explanation for this discrepancy would be that human leukocytes have a membrane-associated C5-9 complex (35). Human kallikrein might therefore release C5a from membrane-bound C5 and thus appear to be chemotactic in the assay system. It is possible that the concentrations of rabbit kallikrein used in this study were not sufficient to observe this effect with rabbit leukocytes.

Summary

Rabbit plasma kallikrein incubated with rabbit C5 resulted in the generation of chemotactic and secretagogue activity for rabbit neutrophils. This effect on C5 appeared to be due to kallikrein itself and not to a contaminating enzyme, because it could be inhibited by anti-kallikrein IgG or by soybean trypsin inhibitor to the same extent that kinin generation by the same kallikrein preparation was inhibited by these agents. The chemotactic response was consistent with the generation of a C5a-like peptide from C5 because the effect could be partially inhibited by carboxypeptidase N and was related to the generation of a small (~14,000 mol wt) fragment of C5.

No direct chemotactic response was detectable for kallikrein, activated Hageman factor, high-molecular weight kininogen, or intact C5. Incubation of kallikrein, high-molecular weight kininogen, and Hageman factor together, so that activation of all three proteins occurred, did not result in the generation of detectable chemotactic activity.

We wish to acknowledge the skilled technical performance of the chemotaxis assays by Bettina Zanolari and Pamela J. Keeling, and the constructive secretarial help of Betty Goddard.

Received for publication 8 December 1980 and in revised form 18 February 1981.

References

1. Muller-Eberhard, H. J. 1978. Complement: molecular mechanisms, regulation and biologic function. In Molecular Basis of Biological Degradative Processes. R. Berlin, H. Hermann, I. Lepow, and J. Tanzer, editors. Academic Press, Inc., New York. 65.
2. Wiggins, R. C., and C. G. Cochrane. 1979. Hageman factor and the contact activation system. In Chemical Messengers of the Inflammation Process. J. C. Houck, editor. Elsevier North-Holland, Biomedical Press, New York. 179.
3. Cooper, N. R., L. A. Miles, and J. H. Griffin. 1979. Activation of purified C1, the first component of complement, by purified plasma kallikrein and plasmin. Thromb. Haemostasis. 42:251.
4. Kaplan, A. P., A. B. Kay, and K. F. Austen. 1972. A prealbumin activator of prekallikrein. III. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. J. Exp. Med. 135:81.
5. March, S. C., I. Parikh, and P. Cuatrecasas. 1974. A simplified method for cyanogen bromide activation of agarose for affinity chromatography. *Anal. Biochem.* 60:149.

6. Ulevitch, R. J., C. G. Cochrane, and A. R. Johnston. 1980. Rabbit prekallikrein: the purification, biochemical characteristics and mechanism of activation. *Inflammation.* 4:9.

7. Giclas, P. C., P. J. Keeling, and P. M. Henson. 1980. Isolation and characterisation of the third and fifth components of rabbit complement. *Mol. Immunol.* 18:113.

8. Rapp, H. J., and T. Borsos. 1970. The molecular basis of complement action. Appleton-Century-Crofts, New York. 89.

9. Webster, R. O., S. R. Hong, R. B. Johnston, Jr., and P. M. Henson. 1980. Biological effects of the human complement fragments C5a and C5a des arg on neutrophil function. *Immunopharmacology.* 2:201.

10. Keller, H. U., H. Gerber, M. W. Hess, and H. Cottier. 1976. Studies on the regulation of the chemotactic response using a rapid and reliable method for measuring random migration and chemotaxis of neutrophil granulocytes. *Agents Actions.* 6:326.

11. Zigmund, S. H., and J. G. Hirsch. 1973. Leucocyte locomotion and chemotaxis. New methods for evaluation and demonstration of a cell-derived chemotactic factor. *J. Exp. Med.* 137:387.

12. Wiggins, R. G., D. J. Loskutoff, C. G. Cochrane, J. H. Griffin, and T. S. Edgington. 1980. Activation of rabbit Hageman factor by homogenates of rabbit endothelial cells. *J. Clin. Invest.* 65:197.

13. Weber, K., J. R. Pringle, and M. Osborn. 1972. Methods in Enzymology. C. H. W. Hirs and S. N. Timasheff, editors. Academic Press, Inc., New York. 263.

14. Lowry, O. H., N. S. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the folin phenol reagent. *J. Biol. Chem.* 193:265.

15. McConahey, P. J., and F. J. Dixon. 1966. A method of trace iodination of proteins for immunologic studies. *Int. Arch. Allergy Appl. Immunol.* 29:185.

16. Henson, P. M. 1971. The immunologic release of constituents from neutrophil leucocytes. I. The role of antibody and complement on nonphagocytosable surfaces or phagocytosable particles. *J. Immunol.* 107:1535.

17. Henson, P. M., B. Zanolari, N. A. Schwartzman, and S. R. Hong. 1978. Intracellular control of human neutrophil secretion. I. C5a-induced stimulus-specific desensitisation and the effects of cytochalasin B. *J. Immunol.* 121:851.

18. Keller, H. U., E. A. Back, M. W. Hess, and H. Cottier. 1977. Significance of Hageman factor (coagulation Factor XII) for neutrophil locomotion and chemotaxis. *Int. Arch. Allergy Appl. Immunol.* 55:309.

19. Goetz, E. J., I. Gigli, S. Wasserman, and K. F. Austen. 1973. A neutrophil immobilizing factor derived from human leucocytes. II. Specificity of action on polymorphonuclear leucocyte mobility. *J. Immunol.* 111:938.

20. Goetz, E. J., and K. F. Austen. 1974. Stimulation of human neutrophil leucocyte aerobic glucose metabolism by purified chemotactic factors. *J. Clin. Invest.* 53:591.

21. Weiss, A. S., J. I. Gallin, and A. P. Kaplan. 1974. Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation. *J. Clin. Invest.* 53:622.

22. Fernandez, N. H., and T. E. Hugli. 1978. Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. *J. Biol. Chem.* 253:6955.

23. Morrison, D. C., and C. G. Cochrane. 1974. Direct evidence for Hageman factor (Factor XII) activation by bacterial lipopolysaccharides (endotoxins). *J. Exp. Med.* 140:797.

24. Niewiarowski, S., E. Rankowski, and I. Rogowicka. 1968. Studies on the adsorption and activation of Hageman factor (Factor XII) by collagen and elastin. *Thromb. Diath. Haemorrh.* 14:387.
25. Wilner, G. D., H. C. Nossel, and E. C. Leroy. 1968. Activation of Hageman factor by collagen. J. Clin. Invest. 47:2608.
26. Soltay, M. J., H. Z. Movat, and A. H. Ozge-Anwar. 1971. The kinin system of human plasma. V. The probable derivation of prekallikrein activator from activated Hageman factor (XIIa). Proc. Soc. Exp. Biol. Med. 138:952.
27. Cochrane, C. G., S. D. Revak, B. S. Aiken, and K. D. Wuepper. 1972. The structural characteristics and activation of Hageman factor. In Inflammation. Mechanisms and Control. I. M. Lepow and P. A. Ward, editors. Academic Press, Inc., New York 119.
28. Kellermeyer, R. W., and R. T. Breckenridge. 1965. The inflammatory processes in acute gouty arthritis. I. Activation of Hageman factor by sodium urate crystals. J. Lab. Clin. Med. 65:307.
29. Wiggins, R. C., B. N. Bouma, C. G. Cochrane, and J. H. Griffin. 1977. Role of high molecular weight kininogen in surface binding and activation of coagulation Factor XI and prekallikrein. Proc. Natl. Acad. Sci. U. S. A. 74:4636.
30. Webster, R. O., B. Zanolari, and P. M. Henson. 1980. Neutrophil chemotaxis in response to surface bound human C5a. Exp. Cell. Res. 129:55.
31. Ward, P. A., C. G. Cochrane, and H. J. Muller-Eberhard. 1965. The role of serum complement in chemotaxis of leukocytes in vivo. J. Exp. Med. 122:327.
32. Ward, P. A., and L. J. Neuman. 1969. A neutrophil chemotactic factor from C5. Immunology. 102:93.
33. Snyderman, R., H. S. Shier, and M. S. Housman. 1971. A chemotactic factor for mononuclear phagocytes. Proc. Soc. Exp. Biol. Med. 138:387.
34. Snyderman, R., J. K. Phillips, and S. E. Mergenhagen. 1971. Biological activity of complement in vivo. Role of C5 in the accumulation of polymorphonuclear leukocytes in inflammatory exudates. J. Exp. Med. 134:1131.
35. Sundsmo, J. S., W. P. Kolb, and H. J. Muller-Eberhard. 1978. Leukocyte complement: neoantigens of the membrane attack complex on the surface of human leukocytes prepared from defibrinated blood. J. Immunol. 120:850.